Phase 2 N=100 Quercetin in Coronary Artery By-pass Surgery
Coronary Artery Disease
Primary: Quercetin-associated Change in Surgery-associated Inflammation — 9; 3; 87; 109 mg/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=79 A Study to Assess the Use of Methylone in the Treatment of PTSD
Post Traumatic Stress Disorder
Primary: Change From Baseline in CAPS-5 Total Severity Score — -36.2; -23.3; -13.6 points — p=0.011
Phase 2 N=149 Intravenous Iron Supplement for Iron Deficiency in Patients With Severe Aortic Stenosis
Severe Aortic Stenosis · Iron-deficiency
Primary: Submaximal Exercise Test — 375; 384 meters
Phase 2 N=69 Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer
Pancreatic Metastatic Cancer · Toxicity
Primary: Composite Safety and Early Efficacy Assessment in the First 34 Patients — 65.8 pourcentage of participants
Phase 2 N=50 Lipoic Acid Supplement for Cystine Stone
Cystinuria
Primary: Cystine Stone Recurrence — 16; 23 Participants
Phase 2 N=9 Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
Clostridium Difficile Infection · Hematologic Diseases · Bone Marrow Transplant
Primary: Changes in Clostridium Difficile Bacterial Loads in the Stool — 62102500.00; 40000000.00; 7752750.00; 185000.00 CFUs
Phase 2 N=5 Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm
Parkinsonian Signs in Older Persons
Primary: Average Gait Speed — 0.81; 0.86; 0.86 meters per second
Phase 2 N=67 Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)
Gastric Cancer by AJCC V8 Stage · Resectable Carcinoma
Primary: Pathologic Response After Pre-operative Treatment — 20 Participants
Phase 2 N=33 Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)
Fabry Disease
Primary: Incidence of Treatment-emergent Adverse Events (TEAEs) - All — 2; 2; 3; 2 Participants
Phase 2 N=32 INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)
Respiratory Papillomatosis
Primary: Percentage of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs — 33.3; 66.7; 75.0; 62.5 percentage of participants
Phase 2 N=55 Fluoxetine Mitigation Mental Health Study for Patients With Musculoskeletal Trauma
Musculoskeletal Injury
Primary: BDI-II - Beck Depression Inventory-II — 11.4; 12.8; 9.6; 11.5 units on a scale
Phase 2 N=30 The Efficacy Of SCH1 In The Treatment Of Acute Infectious Conjunctivitis
Acute Infectious Conjunctivitis (Disorder)
Primary: Complete Clinical Resolution — 9; 0 Participants
Phase 2 N=211 Triple in Asthma Dose Finding
Asthma
Primary: FEV1 AUC0-12h Normalised by Time on Day 42 — 2.327; 2.332; 2.272; 2.296 liters — p=<0.001
Phase 2 N=64 AASUR in High Risk Prostate Cancer
Prostate Cancer
Primary: Number of Participants With Biochemical Failure — 12; 52 Participants
Phase 2 N=81 Safety and Efficacy of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery.
Postoperative Wound Infection Superficial Incisional · Postoperative Wound Infection Deep Incisional Surgical Site
Primary: Decrease of Infection Rate as Measured by the Proportion of Subjects With at Least 1 Identified Sternal Infection Within 90 Days Post-cardiac Surgery. — 0; 4.8…